Durability of HBeAg Seroconversion After Treatment with Entecavir or Tenofovir in Chronic Hepatitis B Patients

被引：0
|
作者：
Fong, Tse-Ling [1 ,2 ]
Mena, Edward A. [3 ]
Yu, Andy S.
Quang-Quoc Phan
Han, Steven-Huy B. [4 ]
Tien, Andy [1 ]
Velasco, Andrew J. [1 ]
Leduc, Vinh-Huy [1 ]
Tong, Myron J. [3 ,4 ]
机构：
[1] St Vincents Med Ctr, Asian Pacific Liver Ctr, Los Angeles, CA USA
[2] Univ So Calif, Los Angeles, CA USA
[3] Huntington Med Res Inst, Pasadena, CA USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
HEPATOLOGY | 2014年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1912
引用
收藏
页码：1121A / 1122A
页数：2
相关论文
共 50 条
  • [21] Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation
    Lee, CM
    Ong, GY
    Lu, SN
    Wang, JH
    Liao, CA
    Tung, HD
    Chen, TM
    Changchien, CS
    JOURNAL OF HEPATOLOGY, 2002, 37 (05) : 669 - 674
  • [22] Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment
    Wong, Grace Lai-Hung
    Chan, Henry Lik-Yuen
    Tse, Yee-Kit
    Yip, Terry Cheuk-Fung
    Lam, Kelvin Long-Yan
    Lui, Grace Chung-Yan
    Szeto, Cheuk-Chun
    Wong, Vincent Wai-Sun
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (09) : 984 - 992
  • [23] Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients - authors' reply
    Yaghoobi, M.
    Yuan, Y.
    Hunt, R. H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (09) : 993 - 993
  • [24] Prolonged Entecavir Therapy Is Not Effective for HBeAg Seroconversion in Treatment-Naive Chronic Hepatitis B Patients with a Partial Virological Response
    Lee, Hyun Woong
    Kwon, Jae-Cheol
    Oh, In Soo
    Chang, Hye Young
    Cha, Young Joo
    Choi, Ik-Seong
    Kim, Hyung Joon
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (09) : 5348 - 5356
  • [25] Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir
    Ezequiel Ridruejo
    World Journal of Gastroenterology, 2014, (23) : 7169 - 7180
  • [26] Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir
    Ridruejo, Ezequiel
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (23) : 7169 - 7180
  • [27] Three-year durability of HBeAg and HBsAg seroconversion after lamivudine for chronic hepatitis B (CHB).
    Willems, B
    Cianciara, J
    Karayalcin, S
    Kowdley, KV
    Plisek, S
    Woessner, M
    McMullen, S
    Gardner, S
    Schiff, E
    HEPATOLOGY, 2001, 34 (04) : 315A - 315A
  • [28] Is HBeAg Seroconversion a Valid Surrogate Marker for Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Lamivudine or Entecavir?
    An, Jihyun
    Kim, Hwa Jung
    Lim, Young-Suk
    Suh, Dong Jin
    HEPATOLOGY, 2014, 60 : 998A - 998A
  • [29] Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment
    Renyong Guo
    Hejun Mao
    Xiao Hu
    Nengneng Zheng
    Dong Yan
    Jianqin He
    Jiezuan Yang
    Scientific Reports, 6
  • [30] Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment
    Guo, Renyong
    Mao, Hejun
    Hu, Xiao
    Zheng, Nengneng
    Yan, Dong
    He, Jianqin
    Yang, Jiezuan
    SCIENTIFIC REPORTS, 2016, 6
12345